Savara, Inc. (SVRA)

4.81 -0.25 (-4.94%) USD  |  NASDAQ  |  Jun 09, 11:51
More

Savara SG&A Expense (Quarterly) : 15.57M for March 31, 2026

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for SVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Marker Therapeutics, Inc. 1.230M
SELLAS Life Sciences Group, Inc. 4.123M
Viridian Therapeutics, Inc. 38.68M
KalVista Pharmaceuticals, Inc. 48.80M
Spyre Therapeutics, Inc. 15.23M